Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

South Africa revises rules around customisation of weight-loss drugs

14 October 2026 · By · Wire by Fusion42

Published

14 October 2026

Topic

regulatory

◆ Sectors

Health

◆ Geography

South Africa

◆ Source

Read at kfgo.com →

◆ Verified

Fusion42 · 14 October 2026 · Fusion42 review

South Africa is updating regulations to restrict pharmacies from compounding weight-loss and diabetes drugs, including GLP-1 treatments, to prevent pharmacies acting as small-scale manufacturers and reduce counterfeit risks.

This Wire brief sits within Fusion42's coverage of Health, and 3 sources have reported it between 14 Oct 2026 and 15 Oct 2026.

◆ ◆ The Wire takeaway

You must review your pharmacy's compounding practices in South Africa now as new rules will limit custom drug preparations, especially for GLP-1 weight-loss meds, reshaping market access and compliance risk.

◆ Coverage

3 sources · first reported 14 Oct 2026 · latest 15 Oct 2026

◆ Related on Wire

◆ Topics

Healthglp-1pharmaceutical-regulationweight-loss-drugscompoundingsahpra